Clinical trial
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients…
NCT00448539 · Eisai Inc., Industry · Terminated
Key facts
| NCT number | NCT00448539 |
|---|---|
| Title | Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures |
| Official title | An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures |
| Lead sponsor | Eisai Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Refractory Partial Onset Seizures |
| Intervention type | Drug |
| Interventions | Rufinamide |
| Enrollment | 286 |
| Start date | Mar 15, 2007 |
| Primary completion | May 14, 2010 |
| Completion | May 14, 2010 |
| First posted | Mar 19, 2007 |
| Last update posted | Nov 22, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: